Inoue T, Koyama T
Department of Psychiatry, Neural Function, Hokkaido University Graduate School of Medicine.
Nihon Rinsho. 2001 Aug;59(8):1530-4.
Monoamine oxidase(MAO) inhibitors had been used in the treatment of depression since 1950s, but there is no MAO inhibitor available clinically in Japan. Liver dysfunction and tyramine's effect are main problems with MAO inhibitors. Reversible inhibitors of MAO-A(RIMA), new and improved MAO inhibitors, were developed and are widely used in Europe. RIMA causes less tyramine's effect and less liver dysfunction than classical MAO inhibitors do. Moclobemide, a RIMA, is under development in Japan(Phase II). An introduction of RIMA in Japan will be useful for the treatment of refractory depression and other anxiety disorders. We discussed pharmacological properties, clinical efficacy and safety of RIMA.
自20世纪50年代以来，单胺氧化酶（MAO）抑制剂一直用于治疗抑郁症，但在日本临床上尚无可用的MAO抑制剂。肝功能障碍和酪胺效应是MAO抑制剂的主要问题。新型改良的MAO抑制剂——单胺氧化酶A可逆抑制剂（RIMA）已被研发出来，并在欧洲广泛使用。与传统MAO抑制剂相比，RIMA引起的酪胺效应和肝功能障碍更少。吗氯贝胺作为一种RIMA，正在日本进行二期研发。在日本引入RIMA将有助于治疗难治性抑郁症和其他焦虑症。我们讨论了RIMA的药理特性、临床疗效和安全性。
